Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects ≥ 18 years~* Subjects who have received oral vitamin K-antagonist therapy~* Subjects who have acute major bleeding, defined as one of the following: life-threatening or potentially life-threatening, acute bleeding associated with a fall in hemoglobin (Hb) level ≥ 2g/dL, bleeding requiring blood product transfusion~* INR ≥ 2 within 3 hours before start of study treatment~* Informed consent has been obtained~Exclusion Criteria:~* Expected survival of less than 3 days, or expected surgery in less than 1 day~* Acute trauma for which reversal of vitamin K antagonists alone would not be expected to control the acute bleeding event~* Use of unfractionated or low molecular weight heparin use from 24 hours prior to enrollment or expected need within 24 hours after start of infusion~* For patients with ICH: Glasgow coma score (GCS) \< 7; intracerebral hematoma volume \> 30cc as assessed by ABC/21; for subdural hematomas: maximum thickness ≥ 10 mm, midline shift ≥ 5 mm; for subarachnoid hemorrhage: any evidence of hydrocephalus; infratentorial ICH location; epidural hematomas; intraventricular extension of hemorrhage; modified Rankin score (mRS) of \>3 prior to ICH~* History of thrombotic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within 3 months of enrollment~* Known history of antiphospholipid antibody syndrome or lupus anticoagulant antibodies~* Suspected or confirmed sepsis at time of enrollment~* Administration of whole blood, plasma, plasma fractions or platelets within 2 weeks prior to inclusion into the study~* Large blood vessel rupture (e.g. in advanced cancer patient)~* Pre-existing progressive fatal disease with a life expectancy of less than 2 months~* Known inhibitors to coagulation factors II, VII, IX, or X; or hereditary protein C or protein S deficiency; or heparin-induced, type II thrombocytopenia~* Treatment with any other investigational medicinal product within 30 days prior to inclusion into the study~* Presence or history of hypersensitivity to components of the study medication~* Pregnant or breast-feeding women~* Prior inclusion in this study or any other CSL Behring-sponsored Beriplex study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beriplex® P/N (Type: EXPERIMENTAL): None
- Fresh frozen plasma (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).